Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 19 studies | 23% ± 7% | |
pericyte | 11 studies | 24% ± 7% | |
smooth muscle cell | 11 studies | 21% ± 4% | |
endothelial cell | 10 studies | 27% ± 9% | |
endothelial cell of lymphatic vessel | 7 studies | 21% ± 5% | |
type I pneumocyte | 7 studies | 22% ± 5% | |
myofibroblast cell | 7 studies | 27% ± 7% | |
connective tissue cell | 7 studies | 29% ± 12% | |
astrocyte | 7 studies | 26% ± 10% | |
microglial cell | 6 studies | 20% ± 5% | |
oligodendrocyte precursor cell | 6 studies | 26% ± 11% | |
epithelial cell | 6 studies | 35% ± 15% | |
GABAergic neuron | 6 studies | 37% ± 18% | |
neuron | 5 studies | 33% ± 13% | |
glutamatergic neuron | 5 studies | 43% ± 21% | |
interneuron | 5 studies | 36% ± 21% | |
progenitor cell | 4 studies | 21% ± 2% | |
basal cell | 4 studies | 22% ± 3% | |
hepatocyte | 4 studies | 41% ± 19% | |
pancreatic A cell | 3 studies | 52% ± 29% | |
abnormal cell | 3 studies | 34% ± 16% | |
GABAergic interneuron | 3 studies | 20% ± 2% | |
club cell | 3 studies | 18% ± 3% | |
type II pneumocyte | 3 studies | 19% ± 2% | |
retina horizontal cell | 3 studies | 28% ± 6% | |
ciliated cell | 3 studies | 25% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 3824.98 | 245 / 245 | 99% | 83.84 | 498 / 502 |
brain | 99% | 2814.32 | 2624 / 2642 | 100% | 75.97 | 703 / 705 |
adrenal gland | 100% | 10747.53 | 258 / 258 | 98% | 86.65 | 226 / 230 |
thymus | 100% | 5476.73 | 653 / 653 | 98% | 77.61 | 590 / 605 |
liver | 100% | 3211.89 | 226 / 226 | 97% | 54.38 | 393 / 406 |
kidney | 100% | 2789.90 | 89 / 89 | 93% | 40.16 | 840 / 901 |
breast | 100% | 3177.82 | 459 / 459 | 89% | 53.40 | 995 / 1118 |
lung | 99% | 2878.81 | 575 / 578 | 89% | 46.10 | 1033 / 1155 |
pancreas | 94% | 1482.65 | 308 / 328 | 94% | 44.48 | 167 / 178 |
ovary | 100% | 9301.36 | 180 / 180 | 86% | 23.75 | 370 / 430 |
skin | 96% | 2793.05 | 1730 / 1809 | 89% | 55.79 | 422 / 472 |
uterus | 100% | 4079.91 | 170 / 170 | 74% | 40.74 | 341 / 459 |
bladder | 100% | 4389.19 | 21 / 21 | 71% | 34.03 | 359 / 504 |
esophagus | 96% | 3755.60 | 1385 / 1445 | 75% | 27.14 | 137 / 183 |
stomach | 100% | 2716.62 | 359 / 359 | 43% | 10.94 | 123 / 286 |
intestine | 88% | 2864.15 | 849 / 966 | 30% | 8.89 | 158 / 527 |
adipose | 100% | 3175.46 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3916.51 | 1335 / 1335 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 12.84 | 1 / 1 |
muscle | 98% | 1628.52 | 786 / 803 | 0% | 0 | 0 / 0 |
spleen | 95% | 1282.20 | 228 / 241 | 0% | 0 | 0 / 0 |
heart | 93% | 2583.72 | 799 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 79% | 24.83 | 63 / 80 |
tonsil | 0% | 0 | 0 / 0 | 64% | 22.67 | 29 / 45 |
peripheral blood | 0% | 1.06 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006338 | Biological process | chromatin remodeling |
GO_0030182 | Biological process | neuron differentiation |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0007420 | Biological process | brain development |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0090537 | Cellular component | CERF complex |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_1904949 | Cellular component | ATPase complex |
GO_0016589 | Cellular component | NURF complex |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0004386 | Molecular function | helicase activity |
GO_0016787 | Molecular function | hydrolase activity |
GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
GO_0036310 | Molecular function | ATP-dependent DNA/DNA annealing activity |
GO_0005524 | Molecular function | ATP binding |
GO_0031491 | Molecular function | nucleosome binding |
GO_0140658 | Molecular function | ATP-dependent chromatin remodeler activity |
GO_0008094 | Molecular function | ATP-dependent activity, acting on DNA |
GO_0005515 | Molecular function | protein binding |
Gene name | SMARCA1 |
Protein name | Probable global transcription activator SNF2L1 (EC 3.6.4.-) (ATP-dependent helicase SMARCA1) (Nucleosome-remodeling factor subunit SNF2L) (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 1) SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 SMARCA1 protein SMARCA1 protein (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1) |
Synonyms | SNF2L1 SNF2L hCG_1980650 |
Description | FUNCTION: [Isoform 1]: Catalytically inactive when either DNA or nucleosomes are the substrate and does not possess chromatin-remodeling activity . Acts as a negative regulator of chromatin remodelers by generating inactive complexes . .; FUNCTION: [Isoform 2]: Helicase that possesses intrinsic ATP-dependent chromatin-remodeling activity . ATPase activity is substrate-dependent, and is increased when nucleosomes are the substrate, but is also catalytically active when DNA alone is the substrate . Catalytic subunit of ISWI chromatin-remodeling complexes, which form ordered nucleosome arrays on chromatin and facilitate access to DNA during DNA-templated processes such as DNA replication, transcription, and repair . Within the ISWI chromatin-remodeling complexes, slides edge- and center-positioned histone octamers away from their original location on the DNA template . Catalytic activity and histone octamer sliding propensity is regulated and determined by components of the ISWI chromatin-remodeling complexes . The BAZ1A-, BAZ1B-, BAZ2A- and BAZ2B-containing ISWI chromatin-remodeling complexes regulate the spacing of nucleosomes along the chromatin and have the ability to slide mononucleosomes to the center of a DNA template . The CECR2- and RSF1-containing ISWI chromatin-remodeling complexes do not have the ability to slide mononucleosomes to the center of a DNA template . Within the NURF-1 and CERF-1 ISWI chromatin remodeling complexes, nucleosomes are the preferred substrate for its ATPase activity . Within the NURF-1 ISWI chromatin-remodeling complex, binds to the promoters of En1 and En2 to positively regulate their expression and promote brain development . May promote neurite outgrowth . May be involved in the development of luteal cells . . |
Accessions | ENST00000371121.5 A0A0A0MRP6 ENST00000371123.5 P28370 ENST00000371122.8 [P28370-1] Q86UA8 B7ZLQ5 |